<DOC>
	<DOC>NCT02847650</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease</brief_title>
	<detailed_description>The B7601011 study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 88 subjects will be randomized to 2 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Females of nonchildbearing potential and/or male subjects Clinical diagnosis of Parkinson's disease. Parkinson's Disease Hoehn &amp; Yahr Stage IIII inclusive Treatment na√Øve or history of prior incidental treatment with dopaminergic agents for no more than 28 days Able to refrain from any Parkinson's disease medication not permitted by the protocol. History or presence of atypical Parkinsonian syndrome. Severe acute or chronic medical or psychiatric condition or cognitive impairment or laboratory abnormality. Any condition possibly affecting drug absorption. Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Early Parkinson Disease</keyword>
	<keyword>Phase 2</keyword>
</DOC>